 |
OUR SERVICES> CENTRAL NERVOUS SYSTEM |
Proof of Concept, Efficacy and Safety
Pharmaseed Bioservices offers a battery of comprehensive in vitro and in vivo models to establish proof-of-concept for potential treatments of CNS diseases. We provide essential information about the CNS efficacy and safety of any tested compound or technology.
With a broad array of tools at our disposal, including the use of small animals, neurological models, biochemical assays, behavioral testing and preclinical neurotoxicological assays, Pharmaseed provides the most cost-effective and quickest-onset pre-clinical in vitro and in vivo services, with the highest standards of quality and accuracy.
I. Determination of blood brain barrier penetration and CNS safety
Pharmaseed employs an efficient program for the early screening of compounds that can effectively cross the BBB. The program includes in vitro and in vivo models and is based on our vast experience in the field:
 |
In vitro co-culture (trans-well) system for early evaluation of drug penetration through the BBB |
|
In vivo measurement of BBB permeability using tracers and immunohistochemistry methods |
|
Intracranial microdialysis: Measurement of delivery and clearance of markers or drugs subsequent to systemic or central administration in freely moving animals |
 |
Figure I: Opening of the blood brain barrier as a result of intracarotid administration of mannitol (Evans-Blue as a marker). |
II. Determination of predicted CNS activity utilizing a battery of behavioral tests
The CNS disease models provided by Pharmaseed include stroke, SAH, Parkinson’s disease, Alzheimer’s disease, pain, anxiety, epilepsy, head trauma and spinal cord trauma.
Pharmaseed employs a battery of disease-oriented behavioral modalities for assessment of cognitive and motoric functions. Assessments are undertaken in a computerized and video-monitored arena.
In addition to the availability of these CNS disease models, our scientific team has the relevant experience and expertise to set up both newly invented and existing CNS models in rodents.
Figure II: Demonstration of a behavioral tool (water maze and neuroscore)
used by Pharmaseed to test efficacy in the rat stroke model (left image).
|
|
|
|
